secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-023492
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR
----------------------------------------------------------------------------

- Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.
- Cash totaled $1.7M as of Sept 30, 2025; completed convertible preferred stock offering in Nov 2025 for $4M gross, with up to $16M additional over 24 months.
- Initiated pivotal Phase 3 trial (PF614-301) for PF614 in moderate to severe post-surgical pain in July 2025.
- FDA supported PF614-MPAR development for overdose protection labeling and confirmed potential streamlined 505(b)(2) pathway.
- R&D expenses increased to $3.0M from $1.7M YoY; grant revenue fell to $0.5M from $3.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/0001493152-25-023492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315225023492/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer